# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JMP Securities analyst Silvan Tuerkcan reiterates Vor Biopharma (NASDAQ:VOR) with a Market Outperform and maintains $12 pric...
Oppenheimer analyst Matthew Biegler reiterates Vor Biopharma (NASDAQ:VOR) with a Outperform and lowers the price target from...
Wedbush analyst David Nierengarten reiterates Vor Biopharma (NASDAQ:VOR) with a Outperform and maintains $11 price target.
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.37...
Wedbush analyst David Nierengarten reiterates Vor Biopharma (NASDAQ:VOR) with a Outperform and maintains $11 price target.
JMP Securities analyst Silvan Tuerkcan reiterates Vor Biopharma (NASDAQ:VOR) with a Market Outperform and maintains $12 pric...
Stifel analyst Stephen Willey maintains Vor Biopharma (NASDAQ:VOR) with a Buy and lowers the price target from $15 to $12.
Wedbush analyst David Nierengarten reiterates Vor Biopharma (NASDAQ:VOR) with a Outperform and maintains $11 price target.